explore -WSS

explore

author：leisure time 2025-08-12 06:42:40 - browse：66

Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease.

The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.CasX was discovered in CRISPR pioneer Jennifer Doudna’s lab, which subsequently spun out Scribe.

Scribe was planning to announce the news Tuesday, but it was published early Monday by GEN.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： What Congress can do to address the rural doctor shortage

focus

knowledge

WSS

European officials brace for rough respiratory virus season

Biotech lab space demand falls sharply

The stability of $0 premiums in Medicare Advantage

Lawsuit highlights wrinkle for disputes over surprise medical bills

Ukraine and a new approach to mental health in war

CDC picks Alphabet's Verily for wasterwater surveillance contract

entertainment

explore

entertainment

Affirmative action in medical school literally saved lives

Stop Congress from blocking public access to science

Supreme Court strikes down use of affirmative action

How Vertex's cystic fibrosis drug is changing patients' lives

United colonoscopy coverage change 'may cost lives,' doctors say

How AI helped researchers track recovery from depression

Guidelines to prevent youth baseball injuries need more muscle

Drug for rare kidney disease narrowly misses mark in clinical trial

Anesthesiologist group: stop taking Ozempic before surgery

EpiPen alternative approval delay highlights citizen petition issue

entertainment

The stability of $0 premiums in Medicare Advantage

6 solutions to address cancer drug shortages and others

EpiPen alternative approval delay highlights citizen petition issue

Intarcia’s device

FDA panel to weigh approval of NurOwn, controversial ALS drug

CRISPR base editing slashes cholesterol levels in monkeys

focus

hotspot

knowledge

focus